Formycon announces decision on Phase III trial with FYB206 and provides update on potential need to adjust the valuation of FYB202 and FYB201 - Pipelinereview

pipelinereview

Factuality

Ownership

Formycon announces decision on Phase III trial with FYB206 and provides update on potential need to adjust the valuation of FYB202 and FYB201 - Pipelinereview

Formycon terminates Phase III study (“Lotus”) for FYB206 following positive feedback from the U.S. Food and Drug Administration (FDA) Anticipated price reductions for Stelara®1 biosimilars in the U.S. likely to require an adjustment in the valuation of FYB202 Discussions initiated with commercialization partner Sandoz AG on the future U.S. commercialization strategy for FYB201/CIMERLI®2 due to increasing price discounts PLANEGG-MARTINSRIED I Ger…